What Is KLOW Peptide? A Plain-English Overview
The short version
KLOW peptide is a blend of four research chemicals supplied in one vial. The four are KPV, GHK-Cu, BPC-157, and TB-500. Each has been studied on its own — in cells, in rodents, in a small number of human pilots — and each has a published literature you can read. What has not been studied is the combination: no controlled experiment has ever tested all four together, in any species, against any comparator. So KLOW peptide stands at an interesting crossroads — four real research stories that have never been told in the same room.
The typical research vial contains 80 mg total: 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500, and 10 mg KPV. The four molecules remain chemically separate inside the vial. GHK-Cu is the mass-dominant component — roughly 62.5% by mass — a copper-chelated tripeptide that shifts gene expression in fibroblasts at extremely low concentrations. BPC-157 is the angiogenic arm, extensively tested in rodent tendon and gut models. TB-500 is a short synthetic fragment of the native thymosin beta-4 protein, linked in that fuller form to hair-follicle stem cell activation. KPV is a three-amino-acid anti-inflammatory that enters inflamed gut cells via the PepT1 transporter.
Not FDA-approved. Research use only. This site lights each strand by its own studies.
KLOW peptide blend — four molecules, four research lineages
KLOW peptide blend is not a single molecule. It is a co-formulation: four distinct peptide research chemicals dissolved together at fixed mass ratios in one lyophilized vial. Understanding what KLOW is requires understanding what each constituent is.
KPV — the anti-inflammatory tripeptide. KPV (Lys-Pro-Val, CAS 67727-97-3) is the C-terminal three-residue sequence of alpha-MSH (alpha-melanocyte-stimulating hormone). It carries one of the most specific mechanisms in the blend: it is a substrate of the PepT1 (SLC15A1) intestinal di/tripeptide transporter — the same transporter that pulls small food-peptides into gut epithelial cells — which is upregulated in inflamed gut, giving KPV preferential access to the cells it needs to reach [3]. At nanomolar concentrations (billionths of a gram per milliliter), KPV inhibits NF-kappaB nuclear import (NF-kappaB is the master transcription factor driving inflammatory gene expression) and suppresses MAP-kinase inflammatory signaling, reducing TNF-alpha, IL-6, and IL-1beta secretion [3].
GHK-Cu — the matrix-remodeling copper complex. GHK-Cu (Gly-His-Lys Copper(II), CAS 89030-95-5) is a naturally occurring tripeptide first isolated from human plasma by Loren Pickart in 1973. It is the dominant component — 50 of the canonical 80 mg. At low-nanomolar concentrations it modulates expression of approximately 31.2% of human protein-coding genes at a 50%-or-greater change threshold [5], with the strongest signals on extracellular-matrix synthesis (procollagen I and IV, dermatan sulfate, the proteoglycan decorin), antioxidant defense, DNA repair, and inflammatory resolution. It supplies copper for lysyl oxidase (the copper-dependent enzyme that crosslinks collagen fibers into mature load-bearing tissue). Plasma GHK levels fall from about 200 ng/mL at age 20 to about 80 ng/mL by age 60 [4].
BPC-157 — the angiogenic repair peptide. BPC-157 (Body Protection Compound 157, CAS 137525-51-0) is a synthetic 15-amino-acid sequence derived from a partial sequence of a protein found in human gastric juice. Across rodent models it has accelerated healing in tendon [2], muscle, bone, gut, and cornea by activating the VEGFR2/PI3K/Akt/eNOS angiogenic signaling axis — VEGFR2 (vascular endothelial growth factor receptor 2) being the principal receptor that triggers new blood-vessel formation — and by modulating the nitric-oxide system. A 2025 IV safety pilot in two adults found no adverse events at doses up to 20 mg [6].
TB-500 — the actin-binding cytoskeletal fragment. TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to the LKKTET actin-binding motif of the 43-amino-acid native protein thymosin beta-4. G-actin sequestration — binding the monomeric (globular) form of the structural protein actin so it can be rapidly deployed for cell migration — is the proposed cytoskeletal mechanism. Most of the richer data, including the follicle-stem-cell activation story [11], belong to the full-length native Tβ4, not the TB-500 fragment; TB-500 carries the LKKTET motif but lacks the additional domains of the native protein.
KLOW blend — what the combination has not been given. No controlled study has ever tested the four-peptide KLOW combination against monotherapy, against any two- or three-component subset, or against a placebo. A pharmacokinetic mismatch (when co-formulated compounds have very different absorption and clearance rates) is inherent: the tripeptides KPV and GHK-Cu clear far faster than the larger BPC-157, and the TB-500 fragment differs from the native Tβ4 whose pharmacokinetics are better characterized. A single co-formulated vial cannot hold all four components at matched exposures. This is not a reason to ignore the individual literatures — they are real and interesting. It is a reason to hold the combination claim at the honest level of extrapolation it occupies.
KLOW vs GLOW — the fourth strand
KLOW and GLOW are related blends from the same research peptide community. GLOW contains three of the same four components: GHK-Cu, BPC-157, and TB-500. KLOW adds a fourth — KPV, the anti-inflammatory tripeptide — and is also known in some catalogs as a distinct blend specifically because of that fourth arm.
The practical distinction as described in community write-ups is the anti-inflammatory dimension: users who have tried both sometimes describe KLOW as feeling more broadly anti-inflammatory, crediting the KPV arm. This is a community impression, not a head-to-head study result. No controlled experiment has compared KLOW and GLOW in any model.
KLOW is distinct from WOLVERINE (a different multi-peptide research blend with a different constituent set) and is not a GLP-1 or incretin compound. It has no weight-loss mechanism and nothing in any of its four constituent literatures supports a weight-management claim.
See klow results for the component-level evidence set and a side-by-side view of the KLOW four-arm composition versus GLOW.